US009763876B2

(12) **United States Patent**
Cartt et al.

(10) **Patent No.: US 9,763,876 B2**
(45) **Date of Patent: *Sep. 19, 2017**

(54) **ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS**

(71) Applicant: **Hale Biopharma Ventures, LLC**, Encinitas, CA (US)

(72) Inventors: **Steve Cartt**, Union City, CA (US); **David Medeiros**, South San Francisco, CA (US); **Garry Thomas Gwozdz**, Jim Thorpe, PA (US); **Andrew Loxley**, Philadelphia, PA (US); **Mark Mitchnick**, East Hampton, NY (US); **David Hale**, San Diego, CA (US); **Edward T. Maggio**, San Diego, CA (US)

(73) Assignee: **Hale Biopharma Ventures, LLC**, Encinitas, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 17 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/527,613**

(22) Filed: **Oct. 29, 2014**

(65) **Prior Publication Data**

US 2015/0065491 A1 Mar. 5, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/495,942, filed on Jun. 13, 2012, now Pat. No. 8,895,546, which is a continuation-in-part of application No. 12/413,439, filed on Mar. 27, 2009.

(60) Provisional application No. 61/040,558, filed on Mar. 28, 2008, provisional application No. 61/497,017, filed on Jun. 14, 2011, provisional application No. 61/570,110, filed on Dec. 13, 2011.

(51) **Int. Cl.**

A61K 9/00	(2006.01)
A61K 45/06	(2006.01)
A61K 31/355	(2006.01)
A61K 31/5513	(2006.01)
A61K 9/08	(2006.01)
A61K 47/10	(2017.01)
A61K 47/22	(2006.01)
A61K 47/26	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 9/0043*** (2013.01); ***A61K 9/008*** (2013.01); ***A61K 9/08*** (2013.01); ***A61K 31/355*** (2013.01); ***A61K 31/5513*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 47/10*** (2013.01); ***A61K 47/22*** (2013.01); ***A61K 47/26*** (2013.01)

(58) **Field of Classification Search**

CPC A61K 9/0043; A61K 45/06; A61K 9/008; A61K 31/355; A61K 31/5513; A61K

USPC 514/221

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,102,116	A	8/1963	Chase et al.
3,109,843	A	11/1963	Reeder et al.
3,136,815	A	6/1964	Reeder et al.
3,243,427	A	3/1966	Reeder et al.
3,296,249	A	1/1967	Bell
3,299,053	A	1/1967	Archer et al.
3,340,253	A	9/1967	Reeder et al.
3,371,085	A	2/1968	Reeder et al.
3,374,225	A	3/1968	Reeder et al.
3,547,828	A	12/1970	Mansfield et al.
3,567,710	A	3/1971	Fryer et al.
3,609,145	A	9/1971	Moffett
3,722,371	A	3/1973	Boyle
3,849,341	A	11/1974	Lambeiti
3,987,052	A	10/1976	Hester, Jr.
4,280,957	A	7/1981	Walser et al.
4,397,951	A	8/1983	Taki et al.
4,608,278	A	8/1986	Frank et al.
4,748,158	A	5/1988	Biermann et al.
4,826,689	A	5/1989	Violanto et al.
4,868,289	A	9/1989	Magnusson et al.
4,921,838	A	5/1990	Catsimpoolas et al.
4,973,465	A	11/1990	Baurain et al.
4,997,454	A	3/1991	Violante et al.
5,091,188	A	2/1992	Haynes
5,100,591	A	3/1992	Leclef et al.
5,118,528	A	6/1992	Fessi et al.
5,145,684	A	9/1992	Liversidge et al.
5,182,258	A	1/1993	Chiou
5,188,837	A	2/1993	Domb
5,192,528	A	3/1993	Radhakrishnan et al.
5,236,707	A	8/1993	Stewart
5,268,461	A	12/1993	Shoji et al.
5,308,531	A	5/1994	Urfer et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	1303674 A	7/2001
EP	0396777 A1	11/1990

(Continued)

OTHER PUBLICATIONS

CA 2,723,470 Office Action dated Feb. 19, 2015.

(Continued)

Primary Examiner — Adam C Milligan

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,317,010	A	5/1994	Pang et al.
5,369,095	A	11/1994	Kee et al.
5,457,100	A	10/1995	Daniel
5,550,220	A	8/1996	Meyer et al.
5,560,932	A	10/1996	Bagchi et al.
5,639,733	A	6/1997	Koike et al.
5,661,130	A	8/1997	Meezan et al.
5,662,883	A	9/1997	Bagchi et al.
5,665,331	A	9/1997	Bagchi et al.
5,716,642	A	2/1998	Bagchi et al.
5,738,845	A	4/1998	Imakawa
5,780,062	A	7/1998	Frank et al.
5,789,375	A	8/1998	Mukae et al.
5,795,896	A	8/1998	Löfroth et al.
5,814,607	A	9/1998	Patton
5,817,634	A	10/1998	Meezan et al.
5,831,089	A	11/1998	Huber
5,861,510	A	1/1999	Piscopio et al.
5,863,949	A	1/1999	Robinson et al.
5,955,425	A	9/1999	Morley et al.
5,981,719	A	11/1999	Woiszwillo et al.
6,004,574	A	12/1999	Backstrom et al.
6,090,925	A	7/2000	Woiszwillo et al.
6,143,211	A	11/2000	Mathiowitz et al.
6,165,484	A	12/2000	Raad et al.
6,193,985	B1	2/2001	Sonne
6,235,224	B1	5/2001	Mathiowitz et al.
6,254,854	B1	7/2001	Edwards et al.
6,268,053	B1	7/2001	Woiszwillo et al.
6,316,029	B1	11/2001	Jain et al.
6,316,410	B1	11/2001	Barbier et al.
6,375,986	B1	4/2002	Ryde et al.
6,395,300	B1	5/2002	Straub et al.
6,428,814	B1	8/2002	Bosch et al.
6,458,387	B1	10/2002	Scott et al.
6,461,591	B1	10/2002	Keller et al.
6,482,834	B2	11/2002	Spada et al.
6,495,498	B2	12/2002	Niemiec et al.
6,524,557	B1	2/2003	Backstrom et al.
6,607,784	B2	8/2003	Kipp et al.
6,610,271	B2	8/2003	Wermeling
6,616,914	B2	9/2003	Ward et al.
6,627,211	B1	9/2003	Choi et al.
6,794,357	B1	9/2004	Backstrom et al.
6,869,617	B2	3/2005	Kipp
6,884,436	B2	4/2005	Kipp
6,908,626	B2	6/2005	Cooper et al.
6,932,962	B1	8/2005	Backstrom et al.
6,991,785	B2	1/2006	Frey
7,008,920	B2	3/2006	Kimura et al.
7,037,528	B2	5/2006	Kipp
7,132,112	B2	11/2006	Choi et al.
7,434,579	B2	10/2008	Young et al.
8,530,463	B2	9/2013	Cartt
8,895,546	B2	11/2014	Cartt
2001/0042932	A1	11/2001	Mathiowitz et al.
2002/0110524	A1	8/2002	Cowan et al.
2002/0127278	A1	9/2002	Kipp
2002/0141971	A1	10/2002	Frey
2002/0168402	A1	11/2002	Kipp
2003/0017203	A1	1/2003	Crotts et al.
2003/0031719	A1	2/2003	Kipp
2003/0040497	A1	2/2003	Teng et al.
2003/0087820	A1	5/2003	Young et al.
2003/0100755	A1	5/2003	Sham et al.
2003/0118547	A1	6/2003	Vandenberg
2003/0118594	A1	6/2003	Nag et al.
2003/0158206	A1	8/2003	Billotte et al.
2003/0170206	A1	9/2003	Rasmussen et al.
2003/0181411	A1	9/2003	Bosch et al.
2004/0101482	A1	5/2004	Sanders
2004/0115135	A1	6/2004	Quay
2004/0126358	A1	7/2004	Warne et al.
2004/0258663	A1	12/2004	Quay et al.
2005/0130260	A1	6/2005	Linden et al.
2005/0234101	A1	10/2005	Stenkamp et al.
2006/0045869	A1	3/2006	Meezan et al.
2006/0046962	A1	3/2006	Meezan et al.
2006/0046969	A1	3/2006	Maggio
2006/0106227	A1	5/2006	Reddy et al.
2006/0147386	A1	7/2006	Wermeling
2006/0198896	A1	9/2006	Liversidge et al.
2007/0059254	A1	3/2007	Singh
2007/0098805	A1	5/2007	Liversidge
2007/0298010	A1	12/2007	Maggio
2008/0200418	A1	8/2008	Maggio
2008/0248123	A1	10/2008	Swanson et al.
2008/0268032	A1	10/2008	Maggio
2008/0279784	A1	11/2008	Cartt
2008/0299079	A1	12/2008	Meezan et al.
2009/0047347	A1	2/2009	Maggio
2009/0130216	A1	5/2009	Cartt
2009/0163447	A1	6/2009	Maggio
2009/0258865	A1	10/2009	Cartt et al.
2009/0297619	A1	12/2009	Swanson et al.
2009/0304801	A1	12/2009	Liversidge et al.
2010/0068209	A1	3/2010	Maggio
2010/0203119	A1	8/2010	Leane et al.
2010/0209485	A1	8/2010	Maggio
2011/0172211	A1	7/2011	Baek et al.
2011/0257096	A1	10/2011	Maggio
2012/0196941	A1	8/2012	Maggio
2013/0065886	A1	3/2013	Cartt
2014/0128479	A1	5/2014	Maggio
2014/0170220	A1	6/2014	Cartt

FOREIGN PATENT DOCUMENTS

EP	606046		7/1994
EP	00780386		6/1997
EP	0818442		1/1998
EP	931788		7/1999
EP	0945485		9/1999
EP	1004578		5/2000
EP	1208863	A2	5/2002
EP	1417972	A1	5/2004
JP	1-151528		6/1989
JP	2003-505403		2/2003
JP	2005-508939		4/2005
JP	2007-510722		4/2007
JP	2011516425	A	5/2011
WO	WO-90-05719		5/1990
WO	WO-91-19481		12/1991
WO	WO-94-05262	A1	3/1994
WO	WO-95-00151	A1	1/1995
WO	WO-95-31217	A1	11/1995
WO	WO-96-27583		9/1996
WO	WO-96-33172		10/1996
WO	WO-97-14407	A1	4/1997
WO	WO-98-03516		1/1998
WO	WO-98-07697		2/1998
WO	WO-98-30566		7/1998
WO	WO-98-33768		8/1998
WO	WO-98-34915		8/1998
WO	WO-98-34918		8/1998
WO	WO-99-07675		2/1999
WO	WO-99-29667		6/1999
WO	WO-99-52889		10/1999
WO	WO-99-52910		10/1999
WO	WO-00-01390	A1	1/2000
WO	WO-00-74681		12/2000
WO	WO-03004015	A1	1/2003
WO	WO-03-055464		7/2003
WO	WO-2005-018565	A2	3/2005
WO	WO-2005-044234	A2	5/2005
WO	WO-2005-089768		9/2005
WO	WO-2005-117830	A1	12/2005
WO	WO-2006-025882	A2	3/2006
WO	WO-2006-055603		5/2006
WO	WO-2006-075123	A1	7/2006

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	WO-2007-144081	A1	12/2007
WO	WO-2008-027395	A2	3/2008
WO	WO-2009-120933	A2	10/2009
WO	WO-2009121039	A2	10/2009

OTHER PUBLICATIONS

CN 201280039077.9 Office Action dated Dec. 26, 2014.
U.S. Appl. No. 60/148,464, filed Aug. 12, 1999, Noe
Ahsan et al., "Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-β-cyclodextrin, on insulin movement across human bronchial epithelial cells", European Journal of Pharmaceutical. Sciences, 2003; 20: 27-34.
Ahsan et al., "Sucrose cocoate, a component of cosmetic preparations enhances nasal and ocular peptide absorption", Int J Pharm, 2003; 251: 195-203.
Albert et al., "Pharmacokinetics of diphenhydramine in man", J. Pharmacokinet, Biopharm., 3(3):159-170 (1975).
Arnold et al., "Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal eithelial cells", J. Pharm. Sci. 93(9):2205-2213 (2004).
AU application 2009228093 First exam report dated Jul. 19, 2013.
Beam et al., "Blood, Brain, Cerebrospinal Fluid Concentrations of Several Antibiotics in Rabbits with Intact and Inflamed Meninges", Antimicrobal Agents and Chemotherapy, Dec. 1977, pp. 710-716.
Bhairi S.M., "A guide to the properties and uses of detergents in biological systems", *Calbiochem*, pp. 1-42 (2001).
Birkett et al., "Bioavailability and First Pass Clearance", Australian Prescriber, 1991, pp. 14-16, vol. 14.
Birkett et al., "How Drugs are Cleared by the Liver", Australian Prescriber, 1990, pp. 88-89, vol. 13, No. 4.
CA 2,723,470 Office action dated Jun. 7, 2012.
Castro et al., "Ecologically safe A1kyl glucoside-based gemini surfactants", ARKIVOC, xii:253-267 (2005).
Chavanpatil and Vavia, "Nasal drug delivery of sumatriptan succinate", Pharmazie., May 2005:60(5):347-349.
Chen et al., "Peptide Drug Permeation Enhancement by Select Classes of Lipids", presented ath the 45th American Society of Cell Biology, S.F., CA, Dec. 10-14, 2005; 1 page total.
Chen-Quay et al., "Identification of tight junction modulating lipids", J. Pharm. Sci., 98(2):606-619 (2009).
Chiou et al., "Improvement of Systemic Absorption of Insulin Through Eyes with Absorption Enhancers", Journal of Pharmaceutical Sciences, Oct. 1989, pp. 815-818, vol. 78, No. 10.
Chiou et al., "Systemic Delivery of Insulin Through Eyes to Lower the Glucose Concentration", Journal of Ocular Pharmacology, 1989, pp. 81-91, vol. 5, No. 1.
Chinese Patent Office from Application No. CN200980157305.0 dated Jan. 28, 2013.
Davis and Ilium, "Absorption enhancers for nasal drug delivery", Clin. Pharmacokine., 2003:42(13):107-28.
De Vry and Schreiber, "Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action", Neurosci. Biobehav. Rev., 24(3):341-53 (2000).
Definition downloaded Sep. 13, 2012 at the medical-dictionary. thefreedictionary.com/p/encephalin.
Definition of pilus, Merriam-Webster Medical Dictionary, http://www.merriam-webster.com/medical/pilus, accessed online on May 28, 2013.
Definition of villus, Merriam-Webster Medical Dictionary, http://www.merriam-webster.com/medical/villus, accessed online on May 28, 2013.
Drewe et al., "Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether", Br. J. Pharmacol., 108(2):298-303 (1993).
Duquesnoy et al., "Comparative clinical pharmacokinetics of single
Edwards CM., "GLP-1: target for a new class of antidiabetic agents?", J.R. Soc. Med., 97(6):270-274 (2004).
Eley and Triumalashetty, "In vitro assessment of A1kylglycosides as permeability enhancers", AAPS PharmsciTech., 2(3): article 19, pp. 1-7 (2001).
EP application 09723906.5 Extended European search report dated Jun. 3, 2013.
EP08747813 Supplementary Search Report dated Jun. 2, 2010.
European Search Report (ESR) from EP 09 83 5809 dated Nov. 13, 2012.
Fix, "Oral controlled release technology for peptides: status and future prospects", Pharmaceutical Research Dec. 1996;13(12):1760-1764.
Fricker et al., "Permeation enhancement of octreotide by specific bile salts in rats and human subjects: in vitro, in vivo correlations", Br. J. Pharmacol., 117(1):217-23 (1996).
Gordon et al., "Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts", Proceedings of the National Academy of Sciences of the United States of America, Nov. 1985, pp. 7419-7423, vol. 82.
Hathcox and Beuchat, "Inhibitory effects of sucrose fatty acid esters, A1one and in combination with ethylenediaminetetraacetic acid and other organic acids, on viability of *Escherichia coli* 0157:H7", Food Microbiology, vol. 13, Issue 3, 213-225 (1996).
Hovgaard et al., "Insulin Stabilization and GI Absorption", Journal of Controlled Release, Mar. 1992, pp. 99-108, vol. 19, Issue 1-3.
Hovgaard et al., "Stabilization of insulin by A1kylmaltosides. A. Spectroscopic evaluation", International Journal of Pharmaceutics, 132(1-2):107-113 (1996).
Hovgaard et al., "Stabilization of Insulin by A1kylmaltosides. B. Oral Absorption in Vivo in Rats", International Journal of Pharmaceutics, 1996, pp. 115-121, vol. 132.
Hussain et A1, "Absorption enhancers in pulmonary protein delivery." J Control Release. Jan. 8, 2004;94(1):15-24.
International Search Report (ISR) from PCT/US2011/056735 dated Jun. 22, 2012.
JP2010-507633 Office Action dated Oct. 23, 2012.
JP2010-507633 Decision of refusal dated Jul. 9, 2013.
Katzung, B., "Basic and Clinical Pharmacology, 7th Edition", Appleton & Lange: Stamford, Connecticut, 1998, pp. 34-49.
Kissel et al., "Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects." Pharm Res. Jan. 1992;9(1):52-57.
Kite et al., "Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro." J Clin Microbiol. Jul. 2004;42(7):3073-3076.
Lacy, C, et al., "Drug Information Handbook, 7th Edition 1999-2000" Lexi-Comp, Inc., 1999, pp. 163-164.
Lahat et al., "Intranasal midazolam for childhood seizures", The Lancet, 1998; 352: 620.
Lehninger et al., "Principles of Biochemistry with an Extended Discussion of Oxygen-Binding Proteins", 1982, pp. 150-151, Worth Publishers, Inc.
Liu et al., "Interaction between chitosan and A1kyl P-D-glucopyranoside and its effect on their antimicrobial activity", Carbohydrate Polymers. 2004; 56: 243-250.
Maa and Prestrelski, "Biopharmaceutical powders: particle formation and formulation considerations", Curr. Pharm. Biotechnol., 1(3):283-302 (2000).
Material Safety Data Sheet for Anatrace, Inc. product n-Dodecyl-β-d-Maltopyranoside, Anagrade, Dated: Jan. 25, 1994 and Revised: Jul. 15, 2004, hhtp://media.affymetrix.com/estore/browse/level_three)category_and_products.jsp?category=35843 &categoryIdClicked=35843&expand=true&parent=35900, access online on Dec. 13, 2012.
Mathew N.T., "Serotonin 1D (5-HT1D) agonists and other agents in acute migraine", Neurol. Clin., 15(1):61-83 (1997).
Matsumura et al., "Surface activities, biodegradability and antimicrobial properties of n-alkyl glucosides, mannosides and

(56) **References Cited**

OTHER PUBLICATIONS

Moses et al., "Insulin Administered Intranasally as an Insulin-Bite Salt Aerosol—Effectiveness and Reproducibility in Normal and Diabetic Subjects", Diabetes, Nov. 1983, pp. 1040-1047, vol. 32.
Murakami et al., "Assessment of Enhancing AbititY of Medium-Chain A1kyl Saccharides as New Absorption Enhancers in Rat Rectum", International Journal of Pharmaceutics, Feb. 1992, pp. 159-169, vol. 79, Issue 1-3].
Ogiso et al., "Percutaneous Absorption of Elcatonin Chemical and Hypocalcemic Effect in Rat", Chemical & Pharmaceutical Bulletin, Feb. 1991, pp. 449-453, vol. 39, Issue 2, The Pharmaceutical Society of Japan, Tokyo, Japan.
Olesen et al., "The Headaches", *Lippincott Williams & Wilkins*, p. 474 (2005).
Paulsson and Edsman, "Controlled drug release from Gels using surfactant aggregates. II Vesicles formed from mixtures of amphiphilic drugs and oppositely charged surfactants", Pharm, Res., 18(11):1586-1592 (2001).
PCT/US08/62961 Search Report dated Jul. 25, 2008.
PCT/US08/62961 International Preliminary Report on Patentability dated Nov. 10, 2009.
PCT/US09/38696 Search Report dated Sep. 28, 2009.
PCT/US09/38696 International Preliminary Report on Patentability dated Sep. 28, 2010.
PCT/US2012/042311 Search Report dated Aug. 31, 2012.
Phillips, A., "The challenge of gene therapy and DNA delivery", J. Pharm Pharmacology 53: 1169-1174, 2001.
Pillion et al., "Synthetic long-chain A1kyl maltosides and A1kyl sucrose esters as enhancers of nasal insulin absorption", J. Pharm. Sci., 91:1456-1462 (2002).
Pillion et al., "Systemic Absorption of Insulin Delivered Topically to the Rat Eye", Investigative Ophthalmology & Visual Science, Nov. 1991, pp. 3021-3027, vol. 32, Issue 12.
Pirollo et al., "Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies", Cancer Res. 68(5): 1247-1250, 2008.
Richards R.M., "Inactivation of resistant Pseudomonas aeruginosa by antibacterial combinations", J. Pharm. Pharmacol., 23:136S-140S (1971).
Salzman et al., "Intranasal Aerosolized Insulin", The New England Journal of Medicine, Apr. 25, 1985, pp. 1078-1084, vol. 312, Issue 17.
Sanders et al., "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing", Eur. J. Clin. Pharmacol., 30(3):331-334 (1986).
Shim and Kim, "Administration Route Dependent Bioavailability of Interferon-α and Effect of Bile Salts on the Nasal Absorption", Drug Development and Industrial Pharmacy, 19(10):1183-1199 (1993).
Stevens and Guillet, "Use of Glucagon to Treat Neonatal Low-Output Congestive Heart Failure after Maternal Labetalol Therapy", The Journal of Pediatrics, Jul. 1995, pp. 151-153, vol. 127, Issue 1.
Swarbrick et al., Encyclopedia of Pharmaceutical Technology, Informa Health Care, 2nd edition, vol. 1, p. 918 (2002).
Tsuchido et A1,, "Lysis of Bacillus subtilis Cells by Glycerol and Sucrose Esters of Fatty Acids", Applied and Environmental Microbiology. vol. 53, No. 3, 505-508, 1987.
Türker et al., "Nasal route and drug delivery systems", Pharm. World Sci., 26(3):137-42 (2004).
Turton et al., "A role for glucagon-like peptide-1 in the central regulation of feeding", Nature, 1996; 379:69-72.
U.S. Appl. No. 12/116,842 Office action mailed May 25, 2011.
U.S. Appl. No. 12/116,842 Office action mailed Apr. 2, 2013.
U.S. Appl. No. 12/116,842 Office action mailed Nov. 15, 2011.
U.S. Appl. No. 12/116,842 Office action mailed Dec. 17, 2013.
U.S. Appl. No. 12/266,529 Office action mailed Jul. 10, 2012.
U.S. Appl. No. 12/266,529 Office action mailed Nov. 16, 2011.
U.S. Appl. No. 12/413,439 Office action mailed Mar. 18, 2011.
U.S. Appl. No. 12/413,439 Office action mailed Nov. 21, 2011.
U.S. Appl. No. 12/413,439 Office action mailed Jun. 19, 2014.
U.S. Appl. No. 13/495,942 Office Action mailed Oct. 1, 2013.
Vidal et al., "Making sense of antisense", European Journal of Cancer, 41:2812-2818, 2005.
Watanabe et al., "Antibacterial Carbohydrate Monoesters Suppressing Cell Growth of *Streptoccus mutans* in the Presence of Sucrose", Current Microbiology, Sep. 2000, pp. 210-213, vol. 41, No. 3.
Weber and Benning, "Metabolism of orally administered A1kyl beta-glycosides in the mouse", J. Nutr., 114:247-254 (1984).
Webpage for Anatrace products of Affymetrix, http://www.affymetrix.com/estore/browse/level_three_category_and_products.jsp?category=35843&categoryIdClicked=35843&expand=true&parent=35900, accessed online on Dec. 13, 2012.
Wermeling et al., "Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers," Anesthesia & Analgesia 103(2):344-349 (2006).
Yamamoto et al., "The Ocular Route for Systemic Insulin Delivery in the A1bino Rabbit", The Journal of Pharmacology and Experimental Therapeutics, Apr. 1989, pp. 249-255, vol. 249; No. 1.
Yu Xinrui et al., "Triptan Medicament and Migraine", World Pharmacy (Synthetic Drug and Biochemical Drug Formulation Fascicule), 22(2):91-92 (2001).
Canadian Patent Application No. 2756690 Examiner's Report dated Oct. 20, 2015.
Chinese Patent Application No. 201280039077.9 Office Action dated Nov. 21, 2016.
Chinese Patent Application No. 2012800390779 Second Office Action dated Aug. 11, 2015.
Chinese Patent Application No. 201280039077.9 Third Office Action dated Mar. 17, 2016.
European Patent Application No. 12801372.9 Extended EP Search Report dated Mar. 26, 2015.
European Patent Application No. 12801372.9 Communication dated Jul. 5, 2016.
Japanese Patent Application No. 2014-515967 Office Action dated Mar. 30, 2016.
Japanese Patent Application No. 2014-515967 Office Action dated Nov. 28, 2016.
Newman. Aerosol deposition consideration in inhalation therapy. Chest 152S-160S (1985).
U.S. Appl. No. 12/413,439 Office Action dated Jul. 14, 2016.
U.S. Appl. No. 12/413,439 Office Action dated Oct. 5, 2015.
U.S. Appl. No. 14/948,081 Office Action dated Oct. 31, 2016.
U.S. Appl. No. 12/116,842 Office Action mailed Jul. 8, 2015.
U.S. Appl. No. 14/021,988 Office Action mailed May 22, 2015.

Figure 1



DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.